Publications
-
- Paper publication
- Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice. PLoS One. 2015 Dec 3;10(12):e0144064. doi: 10.1371/journal.pone.0144064. PMID: 26633898; PMCID: PMC4669177.Chae YN, Kim TH, Kim MK, Shin CY, Jung IH, Sohn YS, Son MH.
-
- Paper publication
- In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations. Molecules. 2015 Dec 4;20(12):21802-15. doi: 10.3390/molecules201219808. PMID: 26690104; PMCID: PMC6332232.Jeong HU, Kim JH, Lee DY, Shim HJ, Lee HS.
-
- Paper publication
- DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012 Jan 2;90(1-2):21-9. doi: 10.1016/j.lfs.2011.10.007. Epub 2011 Oct 20. PMID: 22056373.Kim MK, Chae YN, Kim HD, Yang EK, Cho EJ, Choi SH, Cheong YH, Kim HS, Kim HJ, Jo YW, Son MH, Kim SH, Shin CY.
-
- Paper publication
- Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3809-12. doi: 10.1016/j.bmcl.2011.04.029. Epub 2011 Apr 13. PMID: 21570283.Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, Shin CY, Kim MK, Choi SH, Kim HS, Yang EK, Cheong YH, Chae YN, Park KJ, Jang JM, Choi SJ, Son MH, Kim SH, Yoo M, Lee BJ.
-
- Paper publication
- Pharmacological evaluation and safety of a donepezil patch. Pharmazie. 2020 Dec 1;75(12):656-661. doi: 10.1691/ph.2020.0588. PMID: 33303060.Shin CY, Kim HS, Cha K-, Kim HJ, Choi WS, Jang SW, Sohn UD.
-
- Paper publication
- Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study. Pharmacol Res Perspect. 2023 Feb;11(1):e01040. doi: 10.1002/prp2.1040. PMID: 36734627; PMCID: PMC9897050.Lee DY, Lee MJ, Ryu C, Lee H, Brooks A.
-
- Paper publication
- Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study. Int Neurourol J. 2022 Jun;26(2):119-128. doi: 10.5213/inj.2142382.191. Epub 2022 Jun 30. PMID: 35793990; PMCID: PMC9260321.Son HS, Oh CY, Choo MS, Kim HG, Kim JC, Lee KS, Shin DG, Cho SY, Jeong SJ, Seo JT, Yoon H, Moon HS, Kim JH.
-
- Paper publication
- The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction. BMC Urol. 2020 Apr 17;20(1):41. doi: 10.1186/s12894-020-00611-8. PMID: 32303205; PMCID: PMC7164290. Choi JB, Jeon SH, Kwon EB, Bae WJ, Cho HJ, Ha US, Hong SH, Lee JY, Kim SW.
-
- Paper publication
- Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. Eur J Pharmacol. 2019 Jan 15;843:240-250. doi: 10.1016/j.ejphar.2018.11.037. Epub 2018 Nov 28. PMID: 30502343. Lee MJ, Moon JH, Lee HK, Cho CH, Choi SH, Im WB.
-
- Paper publication
- American Urological Association (AUA) - 111th Annual Meeting (May 6-10, 2016 - San Diego, California, USA).Drugs of today (Barcelona, Spain : 1998) vol. 52,5 (2016): 313-5. doi:10.1358/dot.2016.52.5.2505616. Croasdell, G.